金活醫藥集團(01110.HK):天貓國際金活健康之家海外旗艦店將於1月底正式上線
格隆匯 1 月 11日丨金活醫藥集團(01110.HK)宣佈,天貓國際金活健康之家海外旗艦店("旗艦店")的資格審核已完成,並預期旗艦店將於2021年1月底正式上線。
旗艦店將由公司的全資附屬公司金活藥業健康發展有限公司營運。旗艦店將被計劃作為企業對消費者跨境網上銷售平台,直接向消費者提供於香港註冊的藥品及保健品,包括香港知名止咳產品(包括輕便裝)、眼部護理產品、助消化產品、滋補調養品、營養品及其他知名藥品及保健品。
董事會認為,旗艦店的上線將提升集團的品牌知名度、提高市場滲透率及滿足消費者對高質素之藥品及保健品的需求,並將對公司及其股東整體有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.